Know Cancer

or
forgot password

Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation


N/A
18 Years
N/A
Not Enrolling
Both
Pancreatic Adenocarcinoma

Thank you

Trial Information

Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation


Compared with current clinical practice, the individually optimized CE 4D-CT can potentially
provide much improved tumor-to-parenchyma conspicuity of pancreatic adenocarcinoma. This
will help the radiation oncologists or radiologists to contour the tumor with higher
precision and confidence, and compute the tumor volume and tumor motion more accurately.


Inclusion Criteria:



1. Patients 18 years old or older

2. Patients with PDA who have not had surgical removal of their tumor and who are
planned for treatment with radiotherapy in the Radiation Oncology Department at the
University of Maryland.

3. Patients who have signed the contrast consent form and have been recommended by
physicians to have contrast-enhanced CT scans.

4. Patients who have signed the consent form for this study

Exclusion Criteria:

1. Pregnant or breast-feeding women.

2. Patients with severely decreased renal function19-21.

3. Patients with known severe allergic reactions to contrast.

4. Patients who have difficulty lying flat on their back for extended periods of time.

5. Patients with breaths per minute (BPM) rate less than 10, due to the limitation of
4D-CT image reconstruction software.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Primary Objective Analysis

Outcome Description:

First, experienced radiologists or radiation oncologists specialized in gastrointestinal (GI)/pancreas disease will score the CT images by a qualitative evaluation of: (1) General image quality, in terms of anatomical details, motion artifacts and beam hardening;

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Wei Lu, Ph. D., DABR

Investigator Role:

Principal Investigator

Investigator Affiliation:

UMMC MSGCC

Authority:

United States: Institutional Review Board

Study ID:

HP-00052534

NCT ID:

NCT01764659

Start Date:

March 2013

Completion Date:

December 2014

Related Keywords:

  • Pancreatic Adenocarcinoma
  • 4D-CT
  • Contrast Enhanced CT
  • Radiotherapy Simulation
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous

Name

Location
Ummc Msgcc Baltimore, Maryland  21201